Gyre Therapeutics, Inc.: 5%+ holders

As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Gyre Therapeutics, Inc. The largest reported stake is GNI Group Ltd.'s, at 69.1%. 3 filings are on record since May 6, 2026 (Schedule 13D/A, May 6, 2026).

3 more records on Gyre Therapeutics, Inc. ↓

Sell to companies like Gyre Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filed 2026-05-07 · Holder: Songjiang Ma · Percent: 6.33% · SCHEDULE 13D/A
• Filed 2026-05-06 · Holder: GNI Group Ltd. · Percent: 69.1% · SCHEDULE 13D/A
• Filed 2026-05-06 · Holder: Ying Luo · Percent: 8.6% · SCHEDULE 13D/A

Gyre Therapeutics, Inc. has 3 Schedule 13D or 13G filings on record since 2026-05-06. 3 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Gyre Therapeutics, Inc. and the warning signs.

See Gyre Therapeutics, Inc.'s free Snapshot Watch Gyre Therapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Gyre Therapeutics, Inc. and the records around it.

Gyre Therapeutics, Inc. elsewhere on the record

• Leadership changes Jul 2026
• Acquisition May 2026
• Who owns it

Want the whole picture on Gyre Therapeutics, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Gyre Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Gyre Therapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   5 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Purpose of Transaction (Item 4)

GNI Group Ltd.

Item 4 of the Statement is hereby amended and supplemented as follows: Agreement and Plan of Merger On May 4, 2026 (the "Merger Closing Date"), Gyre consummated the previously announced acquisition of Cullgen Inc., a Delaware corporation ("Cullgen"), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated March 2, 2026 (the "Merger Agreement"), by and among the Company, Helix Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of the Company ("Merger Sub"), and Cullgen. Pursuant to the Merger Agreement, Merger Sub merged with and into Cullgen, with Cullgen continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger (the "Merger"). Under the terms of the Merger Agreement, the Company acquired Cullgen in an all-stock transaction that valued Cullgen at approximately $300 million. At the effective time of the Merger (the "Effective Time"), each then outstanding share of Cullgen capital stock (the "Cullgen Capital Stock"), excluding shares of Cullgen Capital Stock held as treasury stock immediately prior to the Effective Time and any dissenting shares, was converted into (1) with respect to shares of Cullgen Capital Stock held by certain designated holders, (i) for each share of Cullgen common stock ("Cullgen Common Stock") held by such holders, a number of shares of the Series B Preferred Stock, equal to (x) 0.4753 (the "Exchange Ratio") divided by five, and (ii) for each share of …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-05-06; the filing has the rest

Ying Luo

Item 4 of the Statement is hereby amended and supplemented as follows: Agreement and Plan of Merger On May 4, 2026 (the "Merger Closing Date"), Gyre consummated the previously announced acquisition of Cullgen Inc., a Delaware corporation ("Cullgen"), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated March 2, 2026 (the "Merger Agreement"), by and among the Company, Helix Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of the Company ("Merger Sub"), and Cullgen. Pursuant to the Merger Agreement, Merger Sub merged with and into Cullgen, with Cullgen continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger (the "Merger"). Under the terms of the Merger Agreement, the Company acquired Cullgen in an all-stock transaction that valued Cullgen at approximately $300 million. At the effective time of the Merger (the "Effective Time"), each then outstanding share of Cullgen capital stock (the "Cullgen Capital Stock"), excluding shares of Cullgen Capital Stock held as treasury stock immediately prior to the Effective Time and any dissenting shares, was converted into (1) with respect to shares of Cullgen Capital Stock held by certain designated holders, (i) for each share of Cullgen common stock ("Cullgen Common Stock") held by such holders, a number of shares of the Series B Preferred Stock, equal to (x) 0.4753 (the "Exchange Ratio") divided by five, and (ii) for each share of …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-05-06; the filing has the rest

Songjiang Ma

Item 4 of the Statement is hereby amended and supplemented as follows: Agreement and Plan of Merger On May 4, 2026 (the "Merger Closing Date"), Gyre consummated the previously announced acquisition of Cullgen Inc., a Delaware corporation ("Cullgen"), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated March 2, 2026 (the "Merger Agreement"), by and among the Company, Helix Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of the Company ("Merger Sub"), and Cullgen. Pursuant to the Merger Agreement, Merger Sub merged with and into Cullgen, with Cullgen continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger (the "Merger"). Under the terms of the Merger Agreement, the Company acquired Cullgen in an all-stock transaction that valued Cullgen at approximately $300 million. At the effective time of the Merger (the "Effective Time"), each then outstanding share of Cullgen capital stock (the "Cullgen Capital Stock"), excluding shares of Cullgen Capital Stock held as treasury stock immediately prior to the Effective Time and any dissenting shares, was converted into (1) with respect to shares of Cullgen Capital Stock held by certain designated holders, (i) for each share of Cullgen common stock ("Cullgen Common Stock") held by such holders, a number of shares of the Series B Preferred Stock, equal to (x) 0.4753 (the "Exchange Ratio") divided by five, and (ii) for each share of …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-05-07; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Gyre Therapeutics, Inc.

Who owns Gyre Therapeutics, Inc.?

On this page, 3 holders' latest ownership filings report 5% or more of Gyre Therapeutics, Inc.: GNI Group Ltd. (69.1%, Schedule 13D/A, filed 2026-05-06), Ying Luo (8.6%, Schedule 13D/A, filed 2026-05-06) and Songjiang Ma (6.33%, Schedule 13D/A, filed 2026-05-07).

Who are the largest shareholders of Gyre Therapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of Gyre Therapeutics, Inc. on this page are GNI Group Ltd. (69.1%), Ying Luo (8.6%) and Songjiang Ma (6.33%).

When did GNI Group Ltd. buy into Gyre Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from GNI Group Ltd. on this page is the Schedule 13D/A, filed 2026-05-06, reporting 69.1%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Gyre Therapeutics, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Gyre Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Gyre Therapeutics, Inc. is mentioned again
• Find former Gyre Therapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes